MURA 241220 5.00C (MURA241220C5000) Stock Options, News & Quotes

0.05
0.000.00%

15min DelayClose Dec 20 16:00 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Teddy123

Nov 20 17:49

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for Im

$Mural Oncology (MURA.US)$
Mural Oncology's Cancer Drug Shows 33% Response Rate in Melanoma Trial Data | MURA Stock News

Jaguar8

Nov 20 15:19

NEWS

$Mural Oncology (MURA.US)$
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology has published promising clinical data from its completed ARTISTRY-1 phase 1/2 trial of nemvaleukin, showing positive antitumor activity in both monotherapy and combination therapy with pembrolizumab.
The trial, involving 286 patient...

Jaguar8

Nov 7 15:16

NEWS

$Mural Oncology (MURA.US)$
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Mural Oncology presented clinical and preclinical data at the 39th SITC Annual Meeting. The ARTISTRY-3 trial showed that less frequent IV dosing of nemvaleukin demonstrated tumor site-specific immune activation in ovarian cancer and mucosal melanoma patients. Preclinical data from IL-18 variants showed durable immune ...

Jaguar8

Nov 4 13:47

NEWS 13G

$Mural Oncology (MURA.US)$
Mural Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.90%)

Jaguar8

May 23 16:03

$Mural Oncology (MURA.US)$
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...